Vaccines Europe pipeline review

Dashboard

Vaccines Europe conducted a pipeline review of its 14 member companies, including information up to August 2024.

The review shows a promising vaccines pipeline aimed at tackling the challenges of today and tomorrow, such as the burden of respiratory tract infections, AMR, the ageing of the population, climate change and zoonotic infections, through leveraging a broad array of technology platforms.

DOWNLOAD PIPELINE REVIEW

Overview data

98

vaccine candidates in Vaccines Europe membersโ€™ pipeline, of which 93 are prophylactic vaccines and 5 are therapeutic vaccines.

42%

of vaccine candidates aim to address disease areas for which no vaccine has been registered yet.

58%

of the vaccine candidates aim to further develop existing vaccines or find a new approach to address a disease.

30

of the vaccine candidates are for routine immunisation.

4

vaccine candidates aim to treat different types of cancer.

14%

of vaccine candidates are targeting antibiotic resistant pathogens.

Over 80%

of vaccine candidates are tested in adults and older adults.

12

different technology platforms are being used by Vaccines Europe members in their pipelines.

Over 65%

of vaccine candidates aim to tackle respiratory-transmitted diseases.

10%

of vaccine candidates are for travel.

30%

of vaccine candidates are focused on preventing zoonotic diseases.

5

vaccine candidates are for sexually-transmitted infections

Explore the latest vaccines in development

SEARCH BY

all_diseases_area
All Disease Areas
technology_platform
Technology Platforms
development_phases
Development Phases
trial_population
Trial Population

CHOOSE THE DISEASE OR PATHOGEN

acne Acne
clostridioides ๐˜Š๐˜ญ๐˜ฐ๐˜ด๐˜ต๐˜ณ๐˜ช๐˜ฅ๐˜ช๐˜ฐ๐˜ช๐˜ฅ๐˜ฆ๐˜ด ๐˜ฅ๐˜ช๐˜ง๐˜ง๐˜ช๐˜ค๐˜ช๐˜ญ๐˜ฆ infection (CDI)
covid-19 Coronaviruses
cytomegalovirus Cytomegalovirus
dengue-fever Dengue fever
epstein-barr-virus Epstein-Barr virus (EBV) infection
glioblastoma Glioblastoma (CMV-positive)
gonorrhea Gonorrhoea
streptococcus Group B ๐˜š๐˜ต๐˜ณ๐˜ฆ๐˜ฑ๐˜ต๐˜ฐ๐˜ค๐˜ฐ๐˜ค๐˜ค๐˜ถ๐˜ด Infection
hepatitis-b Hepatitis B
herpes-simplex Herpes simplex virus
hiv Human immunodeficiency virus (HIV)
hpv Human papillomavirus (HPV)
influenza Influenza (Seasonal)
influenza pandemic Influenza (Pandemic)
e-coli Invasive ๐˜Œ.๐˜ค๐˜ฐ๐˜ญ๐˜ช Disease
lyme-disease-image Lyme disease (Borreliosis)
measles Measles, Mumps, Rubella, Varicella
malaria Malaria
meningococcal-disease Meningococcal disease
mpox Mpox
nipah-virus Nipah virus (NiV)
norovirus Norovirus
pneumococcal-disease Pneumococcal disease
rabies Rabies
rsv Respiratory Syncytial Virus (RSV)โ€‹
salmonella ๐˜š๐˜ข๐˜ญ๐˜ฎ๐˜ฐ๐˜ฏ๐˜ฆ๐˜ญ๐˜ญ๐˜ข
shigellosis Shigellosis
varicella Varicella-Zoster Virus (VZV)
yellow-fever-e1689505535523-1 Yellow fever
zika-image Zika

CHOOSE A TECHNOLOGY PLATFORM

Generalised Modules for Membrane Antigens
Gonorrhoea ๐˜š๐˜ข๐˜ญ๐˜ฎ๐˜ฐ๐˜ฏ๐˜ฆ๐˜ญ๐˜ญ๐˜ข Shigellosis
Glycoconjugate vaccine
Group B ๐˜š๐˜ต๐˜ณ๐˜ฆ๐˜ฑ๐˜ต๐˜ฐ๐˜ค๐˜ฐ๐˜ค๐˜ค๐˜ถ๐˜ด Infection Invasive ๐˜Œ.๐˜ค๐˜ฐ๐˜ญ๐˜ช Disease Meningococcal disease Pneumococcal disease ๐˜š๐˜ข๐˜ญ๐˜ฎ๐˜ฐ๐˜ฏ๐˜ฆ๐˜ญ๐˜ญ๐˜ข Shigellosis
Live-attenuated virusโ€‹
Dengue fever Measles, Mumps, Rubella, Varicella Respiratory Syncytial Virus (RSV)โ€‹ Varicella-Zoster Virus (VZV) Yellow fever
Monoclonal antibody
Coronaviruses Respiratory Syncytial Virus (RSV)โ€‹
Multiple Antigen Presenting System (MAPS)
Pneumococcal disease
Multiple platforms
Hepatitis B Meningococcal disease
Protein nanoparticles
Coronaviruses Influenza (Seasonal)
Protein subunitโ€‹
Coronaviruses Cytomegalovirus Herpes simplex virus Human papillomavirus (HPV) Lyme disease (Borreliosis) Malaria Respiratory Syncytial Virus (RSV)โ€‹
RNA
Acne Coronaviruses Cytomegalovirus Epstein-Barr virus (EBV) infection Herpes simplex virus Human immunodeficiency virus (HIV) Influenza (Seasonal) Influenza (Pandemic) Lyme disease (Borreliosis) Mpox Nipah virus (NiV) Norovirus Respiratory Syncytial Virus (RSV)โ€‹ Varicella-Zoster Virus (VZV) Zika
Toxoid vaccine
๐˜Š๐˜ญ๐˜ฐ๐˜ด๐˜ต๐˜ณ๐˜ช๐˜ฅ๐˜ช๐˜ฐ๐˜ช๐˜ฅ๐˜ฆ๐˜ด ๐˜ฅ๐˜ช๐˜ง๐˜ง๐˜ช๐˜ค๐˜ช๐˜ญ๐˜ฆ infection (CDI)
Viral vector
Respiratory Syncytial Virus (RSV)โ€‹
Virus-like particleโ€‹
Coronaviruses Cytomegalovirus Glioblastoma (CMV-positive) Hepatitis B Respiratory Syncytial Virus (RSV)โ€‹
Whole-inactivated virusโ€‹
Influenza (Seasonal) Influenza (Pandemic) Rabies Zika

CHOOSE A DEVELOPMENT PHASE

phase-I

Phase I

Acne Coronaviruses Cytomegalovirus Human immunodeficiency virus (HIV) Influenza (Seasonal) Influenza (Pandemic) Lyme disease (Borreliosis) Mpox Nipah virus (NiV) Norovirus Pneumococcal disease Respiratory Syncytial Virus (RSV)โ€‹ ๐˜š๐˜ข๐˜ญ๐˜ฎ๐˜ฐ๐˜ฏ๐˜ฆ๐˜ญ๐˜ญ๐˜ข Varicella-Zoster Virus (VZV) Zika
phase-II

Phase II

๐˜Š๐˜ญ๐˜ฐ๐˜ด๐˜ต๐˜ณ๐˜ช๐˜ฅ๐˜ช๐˜ฐ๐˜ช๐˜ฅ๐˜ฆ๐˜ด ๐˜ฅ๐˜ช๐˜ง๐˜ง๐˜ช๐˜ค๐˜ช๐˜ญ๐˜ฆ infection (CDI) Coronaviruses Cytomegalovirus Dengue fever Epstein-Barr virus (EBV) infection Glioblastoma (CMV-positive) Gonorrhoea Group B ๐˜š๐˜ต๐˜ณ๐˜ฆ๐˜ฑ๐˜ต๐˜ฐ๐˜ค๐˜ฐ๐˜ค๐˜ค๐˜ถ๐˜ด Infection Hepatitis B Herpes simplex virus Human papillomavirus (HPV) Influenza (Seasonal) Influenza (Pandemic) Measles, Mumps, Rubella, Varicella Malaria Meningococcal disease Norovirus Pneumococcal disease Respiratory Syncytial Virus (RSV)โ€‹ ๐˜š๐˜ข๐˜ญ๐˜ฎ๐˜ฐ๐˜ฏ๐˜ฆ๐˜ญ๐˜ญ๐˜ข Shigellosis Varicella-Zoster Virus (VZV) Yellow fever Zika
phase-III

Phase III

๐˜Š๐˜ญ๐˜ฐ๐˜ด๐˜ต๐˜ณ๐˜ช๐˜ฅ๐˜ช๐˜ฐ๐˜ช๐˜ฅ๐˜ฆ๐˜ด ๐˜ฅ๐˜ช๐˜ง๐˜ง๐˜ช๐˜ค๐˜ช๐˜ญ๐˜ฆ infection (CDI) Coronaviruses Cytomegalovirus Influenza (Seasonal) Invasive ๐˜Œ.๐˜ค๐˜ฐ๐˜ญ๐˜ช Disease Lyme disease (Borreliosis) Meningococcal disease Rabies Respiratory Syncytial Virus (RSV)โ€‹
under-review

Under Regulatory Review

Coronaviruses Meningococcal disease

CHOOSE A TRIAL POPULATION

paediatric

Paediatric

Acne ๐˜Š๐˜ญ๐˜ฐ๐˜ด๐˜ต๐˜ณ๐˜ช๐˜ฅ๐˜ช๐˜ฐ๐˜ช๐˜ฅ๐˜ฆ๐˜ด ๐˜ฅ๐˜ช๐˜ง๐˜ง๐˜ช๐˜ค๐˜ช๐˜ญ๐˜ฆ infection (CDI) Coronaviruses Dengue fever Epstein-Barr virus (EBV) infection Gonorrhoea Human papillomavirus (HPV) Influenza (Seasonal) Lyme disease (Borreliosis) Measles, Mumps, Rubella, Varicella Meningococcal disease Pneumococcal disease Rabies Respiratory Syncytial Virus (RSV)โ€‹ Shigellosis Varicella-Zoster Virus (VZV) Yellow fever
adults

Adults

Acne ๐˜Š๐˜ญ๐˜ฐ๐˜ด๐˜ต๐˜ณ๐˜ช๐˜ฅ๐˜ช๐˜ฐ๐˜ช๐˜ฅ๐˜ฆ๐˜ด ๐˜ฅ๐˜ช๐˜ง๐˜ง๐˜ช๐˜ค๐˜ช๐˜ญ๐˜ฆ infection (CDI) Coronaviruses Cytomegalovirus Dengue fever Epstein-Barr virus (EBV) infection Glioblastoma (CMV-positive) Gonorrhoea Group B ๐˜š๐˜ต๐˜ณ๐˜ฆ๐˜ฑ๐˜ต๐˜ฐ๐˜ค๐˜ฐ๐˜ค๐˜ค๐˜ถ๐˜ด Infection Hepatitis B Herpes simplex virus Human immunodeficiency virus (HIV) Human papillomavirus (HPV) Influenza (Seasonal) Influenza (Pandemic) Lyme disease (Borreliosis) Malaria Meningococcal disease Mpox Nipah virus (NiV) Norovirus Pneumococcal disease Rabies Respiratory Syncytial Virus (RSV)โ€‹ ๐˜š๐˜ข๐˜ญ๐˜ฎ๐˜ฐ๐˜ฏ๐˜ฆ๐˜ญ๐˜ญ๐˜ข Shigellosis Varicella-Zoster Virus (VZV) Yellow fever Zika
older-adults

Older Adults

๐˜Š๐˜ญ๐˜ฐ๐˜ด๐˜ต๐˜ณ๐˜ช๐˜ฅ๐˜ช๐˜ฐ๐˜ช๐˜ฅ๐˜ฆ๐˜ด ๐˜ฅ๐˜ช๐˜ง๐˜ง๐˜ช๐˜ค๐˜ช๐˜ญ๐˜ฆ infection (CDI) Coronaviruses Dengue fever Glioblastoma (CMV-positive) Influenza (Seasonal) Influenza (Pandemic) Invasive ๐˜Œ.๐˜ค๐˜ฐ๐˜ญ๐˜ช Disease Norovirus Pneumococcal disease Rabies Respiratory Syncytial Virus (RSV)โ€‹ Varicella-Zoster Virus (VZV) Yellow fever

N/A

Coronaviruses Pneumococcal disease

OR SEARCH BY REPORT SECTIONS

ico-antimicrobal
Antimicrobal resistance

CHOOSE THE DISEASE OR PATHOGEN

clostridioides ๐˜Š๐˜ญ๐˜ฐ๐˜ด๐˜ต๐˜ณ๐˜ช๐˜ฅ๐˜ช๐˜ฐ๐˜ช๐˜ฅ๐˜ฆ๐˜ด ๐˜ฅ๐˜ช๐˜ง๐˜ง๐˜ช๐˜ค๐˜ช๐˜ญ๐˜ฆ infection (CDI)
e-coli Invasive ๐˜Œ.๐˜ค๐˜ฐ๐˜ญ๐˜ช Disease
pneumococcal-disease Pneumococcal disease
salmonella ๐˜š๐˜ข๐˜ญ๐˜ฎ๐˜ฐ๐˜ฏ๐˜ฆ๐˜ญ๐˜ญ๐˜ข
shigellosis Shigellosis
ico-climate-change
Climate change

CHOOSE THE DISEASE OR PATHOGEN

dengue-fever Dengue fever
malaria Malaria
zika-image Zika
ico-infection-associated 60×60
Infection-associated cancer vaccines

CHOOSE THE DISEASE OR PATHOGEN

epstein-barr-virus Epstein-Barr virus (EBV) infection
glioblastoma Glioblastoma (CMV-positive)
hpv Human papillomavirus (HPV)
ico-routine-vaccine
Routine vaccines across the lifespan

CHOOSE THE DISEASE OR PATHOGEN

streptococcus Group B ๐˜š๐˜ต๐˜ณ๐˜ฆ๐˜ฑ๐˜ต๐˜ฐ๐˜ค๐˜ฐ๐˜ค๐˜ค๐˜ถ๐˜ด Infection
influenza Influenza (Seasonal)
measles Measles, Mumps, Rubella, Varicella
meningococcal-disease Meningococcal disease
pneumococcal-disease Pneumococcal disease
rsv Respiratory Syncytial Virus (RSV)โ€‹
varicella Varicella-Zoster Virus (VZV)
ico-therapeutic
Therapeutic vaccines

CHOOSE THE DISEASE OR PATHOGEN

glioblastoma Glioblastoma (CMV-positive)
hepatitis-b Hepatitis B
herpes-simplex Herpes simplex virus
ico-travel-vaccines-1
Travel vaccines

CHOOSE THE DISEASE OR PATHOGEN

dengue-fever Dengue fever
meningococcal-disease Meningococcal disease
rabies Rabies
salmonella ๐˜š๐˜ข๐˜ญ๐˜ฎ๐˜ฐ๐˜ฏ๐˜ฆ๐˜ญ๐˜ญ๐˜ข
yellow-fever-e1689505535523-1 Yellow fever
ico-pandemic
Zoonoses and pandemic preparedness

CHOOSE THE DISEASE OR PATHOGEN

covid-19 Coronaviruses
dengue-fever Dengue fever
influenza pandemic Influenza (Pandemic)
lyme-disease-image Lyme disease (Borreliosis)
malaria Malaria
mpox Mpox
nipah-virus Nipah virus (NiV)
rabies Rabies
salmonella ๐˜š๐˜ข๐˜ญ๐˜ฎ๐˜ฐ๐˜ฏ๐˜ฆ๐˜ญ๐˜ญ๐˜ข

Charts

By the end of August 2024, there were 98 vaccine candidates in the Vaccines Europe membersโ€™ pipeline. Most of these target infectious diseases caused by viruses. The majority of vaccine candidates target the adult population, especially for those at higher risk for serious disease infection. Meanwhile, almost half of the vaccine candidates target diseases for which there are no registered vaccines yet.

How can Europe take full advantage of this promising vaccines pipeline?

1
Ensure sustainable immunisation financing in EU Member States
2
Enhance vaccine market access pathways in Europe
3
Embed adult vaccination in national immunisation programmes to improve country readiness

EU Vaccines Pipeline Review

DOWNLOAD PIPELINE REVIEW